| SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (NCT05480865) | Navire Pharma Inc., a BridgeBio company | 2022-07-06 |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) (NCT05384626) | Nuvalent Inc. | 2022-06-09 |
| Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors (NCT05479812) | Werewolf Therapeutics, Inc. | 2022-05-20 |
| Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer (NCT05232409) | Valley Health System | 2022-04-17 |
| Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (NCT05126433) | Jazz Pharmaceuticals | 2022-03-03 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) (NCT05103358) | Aadi Bioscience, Inc. | 2022-02-15 |
| Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors (NCT05279690) | Icahn School of Medicine at Mount Sinai | 2022-02-14 |
| Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population (NCT05863052) | University of Oklahoma | 2022-01-31 |
| A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (NCT05490043) | Antengene (Hangzhou) Biologics Co., Ltd. | 2022-01-30 |
| LAG3 PET Imaging in Advanced Solid Tumors (NCT04706715) | University Medical Center Groningen | 2022-01-18 |
| A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (NCT05081609) | Ascendis Pharma Oncology Division A/S | 2022-01-11 |
| A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) (NCT05118789) | Nuvalent Inc. | 2022-01-04 |
| A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (NCT04986865) | Antengene Biologics Limited | 2021-12-15 |
| A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (NCT04914117) | RemeGen Co., Ltd. | 2021-11-29 |
| A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors (NCT05071183) | Turning Point Therapeutics, Inc. | 2021-09-23 |
| A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer (NCT05004116) | Memorial Sloan Kettering Cancer Center | 2021-08-09 |
| GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors (NCT04977453) | GI Innovation, Inc. | 2021-08-02 |
| A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC (NCT04849273) | Turning Point Therapeutics, Inc. | 2021-07-28 |
| A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors (NCT04801095) | Wellmarker Bio | 2021-07-14 |
| QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT04898543) | ImmunityBio, Inc. | 2021-06-21 |
| Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors (NCT04892017) | Deciphera Pharmaceuticals, LLC | 2021-06-15 |
| A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors (NCT04761198) | Mereo BioPharma | 2021-03-23 |
| A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors (NCT04799054) | Ascendis Pharma Oncology Division A/S | 2021-03-18 |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors (NCT04579757) | Hutchmed | 2021-03-05 |
| Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors (NCT04602702) | Sunnybrook Health Sciences Centre | 2020-12-01 |
| The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors (NCT04614740) | Jiangsu vcare pharmaceutical technology co., LTD | 2020-11-20 |
| Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy (NCT04393454) | Albert Einstein College of Medicine | 2020-11-16 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (NCT04419532) | Daiichi Sankyo | 2020-10-09 |
| Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors (NCT04383210) | Elevation Oncology | 2020-09-29 |
| Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) (NCT04447651) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-09-17 |
| A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer (NCT04474470) | TyrNovo Ltd. | 2020-09-03 |
| Safety and Early Signs of Efficacy of IL12-L19L19. (NCT04471987) | Philogen S.p.A. | 2020-07-01 |
| Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations (NCT04161391) | Turning Point Therapeutics, Inc. | 2019-12-06 |
| Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies (NCT04137900) | TopAlliance Biosciences | 2019-10-30 |
| Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors (NCT03964727) | Gilead Sciences | 2019-10-15 |
| A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers (NCT04761744) | Korean Cancer Study Group | 2019-06-14 |
| PREcision Medicine in Cancer in Odense, Denmark (NCT05385081) | Odense University Hospital | 2019-03-01 |
| Study Evaluating Treatment Adherence in Patients Treated With Oral Targeted Therapy in Oncology Supported by a Dedicated and Coordinated Follow-up Compared to Standard Follow-up. (NCT03263416) | Institut Claudius Regaud | 2017-07-24 |
| HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors (NCT03284502) | Hanmi Pharmaceutical Company Limited | 2017-05-22 |
| A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors (NCT02133625) | Dana-Farber Cancer Institute | 2011-08-01 |
| The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies (NCT01393509) | Memorial Sloan Kettering Cancer Center | 2011-07-06 |
| Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT01390818) | EMD Serono | 2011-05-01 |
| Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors (NCT00611468) | Accelerated Community Oncology Research Network | 2006-06-01 |
| Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors (NCT00997529) | Beth Israel Deaconess Medical Center | 2000-11-01 |